BACKGROUNDS: Limited data are available for the use of robot-assisted partial nephrectomy (RAPN) in tumors >4 cm. The objectives of this study were to report the perioperative outcomes of a series of patients who underwent RAPN for suspicious >4 cm renal tumors and to compare these results with those observed in a group of patients with ≤4 cm tumors. METHODS: We analyzed retrospectively the clinical records of 49 patients who underwent RAPN for suspicious of renal cell carcinoma (RCC) >4 cm in size at four centers from September 2008 to September 2010. All patients underwent da Vinci RAPN. The results were compared with those observed in a group of patients undergoing RAPN for ≤4 cm renal tumors. RESULTS: The median warm ischemia time (WIT) was 22 min (Interquartile range [IQR] 18-28). The median console time was 145 min (median IQR 112-177). The median blood loss was 120 mL (IQR 62-237). In two cases, we observed intraoperative renal vein injury (4 %). Postoperative complications were reported in 13 (26.5 %) patients. Major complications were observed in 4 (8.2 %) cases. Patients with large tumors showed perioperative outcomes worse than those received the RAPN for ≤4 cm tumors. Conversely, no significant difference was observed in positive surgical margin (PSM) rates. CONCLUSIONS: These outcomes support the use of RAPN as possible alternative to open PN for the treatment for patients with suspicious renal masses >4 cm. Positive surgical margin rates demonstrated RAPN is an oncologically safe procedure for tumors >4 cm.
BACKGROUNDS: Limited data are available for the use of robot-assisted partial nephrectomy (RAPN) in tumors >4 cm. The objectives of this study were to report the perioperative outcomes of a series of patients who underwent RAPN for suspicious >4 cm renal tumors and to compare these results with those observed in a group of patients with ≤4 cm tumors. METHODS: We analyzed retrospectively the clinical records of 49 patients who underwent RAPN for suspicious of renal cell carcinoma (RCC) >4 cm in size at four centers from September 2008 to September 2010. All patients underwent da Vinci RAPN. The results were compared with those observed in a group of patients undergoing RAPN for ≤4 cm renal tumors. RESULTS: The median warm ischemia time (WIT) was 22 min (Interquartile range [IQR] 18-28). The median console time was 145 min (median IQR 112-177). The median blood loss was 120 mL (IQR 62-237). In two cases, we observed intraoperative renal vein injury (4 %). Postoperative complications were reported in 13 (26.5 %) patients. Major complications were observed in 4 (8.2 %) cases. Patients with large tumors showed perioperative outcomes worse than those received the RAPN for ≤4 cm tumors. Conversely, no significant difference was observed in positive surgical margin (PSM) rates. CONCLUSIONS: These outcomes support the use of RAPN as possible alternative to open PN for the treatment for patients with suspicious renal masses >4 cm. Positive surgical margin rates demonstrated RAPN is an oncologically safe procedure for tumors >4 cm.
Authors: Jean-Jacques Patard; Allan J Pantuck; Maxime Crepel; John S Lam; Laurent Bellec; Baptiste Albouy; David Lopes; Jean-Christophe Bernhard; François Guillé; Bertrand Lacroix; Alexandre De La Taille; Laurent Salomon; Christian Pfister; Michel Soulié; Jacques Tostain; Jean-Marie Ferriere; Claude C Abbou; Marc Colombel; Arie S Belldegrun Journal: Eur Urol Date: 2007-01-16 Impact factor: 20.096
Authors: Brian M Benway; Sam B Bhayani; Craig G Rogers; James R Porter; Nicolò M Buffi; Robert S Figenshau; Alexandre Mottrie Journal: Eur Urol Date: 2010-01-22 Impact factor: 20.096
Authors: Bradley C Leibovich; Michael L Blute; John C Cheville; Christine M Lohse; Amy L Weaver; Horst Zincke Journal: J Urol Date: 2004-03 Impact factor: 7.450
Authors: Burkhard Ubrig; Alexander Roosen; Christian Wagner; Guenter Trabs; Frank Schiefelbein; Jorn H Witt; Georg Schoen; Nina Natascha Harke Journal: World J Urol Date: 2018-01-29 Impact factor: 4.226
Authors: Matvey Tsivian; Efrat Tsivian; Yury Stanevsky; Roman Bass; A Ami Sidi; Alexander Tsivian Journal: Int Braz J Urol Date: 2017 Sep-Oct Impact factor: 1.541